MedTrace Logo

RELISTOR's Effects on Opioid-Induced Constipation

NCT04930237 · Status: WITHDRAWN · Type: OBSERVATIONAL

Last updated 2026-03-23

No results posted yet for this study

Summary

This will be a prospective case-control study of 40 patients undergoing 1-2 level ALIF procedures at Methodist Dallas Medical Center (MDMC). Patient records will be reviewed to identify details including demographics, comorbidities, procedure details, and the primary and secondary outcome metrics.

Conditions

  • OIC

Interventions

DRUG

Senna

Standard of Care

DRUG

Enema

Standard of Care

DRUG

Relistor Injectable Product

12-mg RELISTOR to be administered as once-daily subcutaneous injections for 4 to 7 days

DRUG

Docusate Calcium

Standard of care

DRUG

Bisacodyl

Standard of Care

DRUG

Milk of magnesia

Standard of Care

DRUG

Magnesium citrate

Standard of Care

Sponsors & Collaborators

  • Methodist Health System

    lead OTHER

Principal Investigators

  • Richard Meyrat, MD · The Methodist Hospital Research Institute

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-07-01
Primary Completion
2022-04-22
Completion
2022-04-22

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04930237 on ClinicalTrials.gov